Most Read Articles
Natalia Reoutova, 2 days ago

Consistent with the overall outcome of the phase III EF-14 study, elderly patients with newly diagnosed glioblastoma multiforme (GBM) treated with tumour-treating fields (TTFields) and temozolomide (TMZ) showed significantly better overall survival (OS) vs patients on TMZ alone, according to a post-hoc analysis presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

Guardant360® ctDNA liquid biopsy for treatment selection of patients with NSCLC

29 May 2020
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Singapore digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 2 days ago

Consistent with the overall outcome of the phase III EF-14 study, elderly patients with newly diagnosed glioblastoma multiforme (GBM) treated with tumour-treating fields (TTFields) and temozolomide (TMZ) showed significantly better overall survival (OS) vs patients on TMZ alone, according to a post-hoc analysis presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.